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A B S T R A C T
RNA transcripts that not undergo translation into polypeptides recently came into focus of research. Long non-
coding RNAs (lncRNAs), microRNAs (miRNAs) and circular RNAs (circRNAs) comprise the most important
groups of these transcripts. LncRNAs have a length over 200 nucleotides and like mRNAs, have regulated
transcription in a tissue specific manner. Biogenesis and function of lncRNAs is related to cell differentiation,
response to stimuli and regulation of immune responses. LncRNAs can interact with both miRNAs and mRNAs.
MiRNAs are characterized by a length of 22–24 nucleotides. MiRNAs regulate expression of genes at the post-
transcriptional level. LncRNAs together with miRNAs are considered as regulators of the immune system.
Alterations in their biogenesis is an important mechanism in the development immune related disorders.
CircRNAs are products of aberrant maturation of protein-coding transcripts in a process of back-splicing, in
which a single strand RNA molecule attains a closed circle shape. Despite a low expression, some circRNA were
found to titrate miRNAs and interfere with maturation of legitimate protein-coding transcripts. We summarize
the current knowledge on the role of non-coding transcripts in allergic disorders: asthma, atopic dermatitis,
allergic rhinitis and urticaria. The reviewed data suggest lncRNA and miRNAs as therapeutic targets and bio-
markers of allergic disorders.
1. Introduction
Some sequences of a genome are transcribed but not translated into
polypeptides. These non-coding RNA (ncRNA) can be detected in the
cytoplasm or in extracellular fluids. Deep RNA sequencing and bioin-
formatics tools allowed to study (ncRNAs). Participation of ncRNA in
RNA splicing, transposon reassembly or genes rearrangements [1] was
known for long time. However, regulatory ncRNAs constitute a large
proportion of ncRNAs. The most recently described circular RNAs are
produced from protein-coding transcripts by abnormal splicing and
have a closed circle shape. Some circRNA were found to trap miRNAs
and interfere with maturation mRNA [2]. Other ncRNA are named long
ncRNAs (lncRNAs, length>200 nucleotides) or microRNAs (miRNAs,
length 22–24 nucleotides) [2,3]. MiRNAs regulate translation of poly-
peptides at post-transcriptional level [4] contributing to epigenetic
regulation. All ncRNAs are encoded by their respective genes and reg-
ulate many biological processes in an evolutionary conserved manner
[5]. Both lncRNAs and miRNAs participate in the regulation of im-
munity by the preservation of hematopoietic stems cells, differentiation
and apoptosis of myeloid cell and the stimulation of monocytes,
macrophages and dendritic cells (DCs) [6]. Moreover, several lncRNAs
regulate proliferation, differentiation and induction of immune cells
from inactive state. During innate or adaptive immune responses
monocytes, macrophages, DCs, neutrophils, T and B lymphocytes
change their expression of ncRNAs [7]. Assessment of expression of
lncRNAs in CD8+ and CD4 + T cells led to identification of numerous
RNAs species with a phase- or tissue-specific signatures [8,9]. Similarly,
miRNAs were showed to alter cell development, differentiation and
release of inflammatory cytokines [10]. The role of miRNAs in reg-
ulation of innate immune responses, especially macrophages and
granulocytes, was well established [11]. MiRNAs also participate in a
control adaptive immune responses and abnormal expression of
miRNAs was found in autoimmune disorders [11]. We summarize the
available data about the role of these ncRNA in asthma, atopic der-
matitis (AD), allergic rhinitis (AR), and urticaria.
2. Asthma
Asthma is an inflammatory disorder of the lower airways with re-
versible obstruction of the airflow and chronic airway remodeling [12].
https://doi.org/10.1016/j.biopha.2020.110615
Received 16 June 2020; Received in revised form 26 July 2020; Accepted 2 August 2020
⁎ Corresponding authors.
E-mail addresses: mohammad_823@yahoo.com (M. Taheri), marek.sanak@uj.edu.pl (M. Sanak).
Biomedicine & Pharmacotherapy 130 (2020) 110615
Available online 07 August 2020
0753-3322/ © 2020 The Author(s). Published by Elsevier Masson SAS. This is an open access article under the CC BY license 
(http://creativecommons.org/licenses/by/4.0/).
T
A histopathological component of asthma is hyperplasia and hyper-
trophy of airway smooth muscle cells (ASMCs). Epigenetic mechanisms
have prominent roles in the regulation of these cells [13]. Austin et al.
reported on differential expression of lncRNAs comparing ASMCs from
patients with non-severe and those with severe asthma. Also, a lower
expression of PVT1 lncRNA was found in patients with corticosteroid-
sensitive non-severe asthma, whereas over-expression of this lncRNA
was present in asthmatics with corticosteroid-insensitive severe phe-
notype. Functional studies showed the role of PVT1 in the regulation of
cell proliferation and IL-6 production of ASMCs [14]. Zhu et al. assessed
expression of lncRNAs in peripheral blood samples of patients with
eosinophilic asthma, neutrophilic asthma and healthy controls using
RNA-sequencing. Several differentially expressed lncRNAs were iden-
tified. Over-expression of LNC_000127 in eosinophilic asthma was re-
plicated in Jurkat immortalized human T lymphocytes and isolated
human CD4 + T cells following stimulation with phorbol ester or anti-
CD28. The function of this lncRNA in Th2 inflammation pathway was
thus verified [15]. Ye et al. examined expression of ANRIL lncRNA in
patients with asthma during exacerbation (BA‐E), patients at remission
(BA‐R) and healthy controls. Of interest, a higher expression of ANRIL/
miR‐125a axis was observed in BA‐E patients compared with BA‐R or
control groups. Expression of this regulatory axis negatively correlated
with respiratory functional tests results in the study participants. An-
other correlation was found between ANRIL/miR‐125a axis expression
and severity of asthma, particularly in exacerbations [16]. In addition,
receiver operating characteristic curve showed that the axis expression
could discriminate disease status with a performance comparable to the
measurements of TNF‐α, IL‐1β, IL‐6 and IL‐17 cytokines [16]. Presented
results are consistent with the role of ANRIL/miR‐125a axis in regula-
tion of immune response and suggest its involvement into the patho-
genesis of asthma [17,18]. Some other studies also reported aberrant
expression of a number of lncRNAs in asthma. Fig. 1A shows the role of
TIMMDC1 and lncTCF7 in the pathophysiology of asthma. Fig. 1B il-
lustrates TUG1 lncRNA in the control of miR-590-5p regulated bron-
chial remodeling. The profile of expression and a tentative function of
lncRNAs in asthma are summarized in the Table 1.
Several studies assessed the role of miRNAs in asthma. A group of
miRNAs which regulate the balance between Th1 and Th2 cells are
particular candidates for immunoregulation of the disease. Qui et al.
evaluated expression of miRNAs that targeted the transcription factor
Runx3 contributing in differentiation of T helper cells. They showed an
imbalance of Th1/Th2 cells in the asthmatic patients they studied.
Moreover, a lower expression of Runx3 and higher expression of a
several miRNAs targeting this transcription factor in the CD4 + T cells
was detected in asthmatic patients. Experimentally, it was verified that
miR-371, miR-138, miR-544, miR-145, and miR-214 could directly bind
to the 3'-UTR of Runx3. These miRNAs could contribute to the Th1/Th2
imbalance in asthma by regulating Runx3 [26].
Several other miRNAs participate in suppression of inflammation in
airways, thus down-regulation of these miRNAs contribute to the pa-
thogenesis of asthma. MiR-21 role in regulation of allergic asthma
model in mouse is illustrated by the Fig. 2. Ma et al. established a mouse
model of asthma by sensitizing and challenging the mice with oval-
bumin. In this animal model, they showed that miR-20b mimic reduced
both the number of the total leukocytes, neutrophils and eosinophils in
the bronchoalveolar lavage fluid (BALF) and mucus production in the
airway. Moreover, this treatment decreased VEGF levels in BALF [53].
The role of some other miRNAs in the pathogenesis of asthma was
evaluated in human subjects. Zhang et al. found decreased abundance
of miR-192 in asthmatic children as compared with controls. In vitro
experiments documented that miR-192 inhibited activation pathway of
T follicular helper cells by targeting CXCR5 [43]. Table 2 shows the list
Fig. 1. (A) TIMMDC1 and lncTCF7 have been shown to be up-regulated in asthma. LncTCF7 enhances transcription of TIMMDC1. Knock-down of lncTCF7 has led to
down-regulation of TIMMDC1 at transcript and protein levels. Up-regulation of TIMMDC1 increases phosphorylation and activation of AKT. Activated AKT increases
expression of β-catenin through inhibition of GSK-3β leading to modulation of expression of genes which are involved in the airway remodeling [19]. (B) TUG1 acts
as a competing endogenous RNA to decrease miR-590-5p levels. miR-590-5p has a role in suppression of FGF1 expression through binding with its 3' UTR region, thus
inhibition of this miRNA by TUG1 increases expression of FGF1. FGF1 is a pro-angiogenic growth factor and vascular endothelial growth factor, therefore it is
involved in the airway remodeling [20].
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Table 1
Expression and function of lncRNAs in asthma.
LncRNA Expression
pattern





PVT1 Upregulated Primary ASMCs from patients with non-severe (n =
9) or severe (n = 9) asthma and healthy subjects
(n = 9)
IL-6 – PVT1 increased in corticosteroid-insensitive severe asthma and
decreased in corticosteroid-sensitive non-severe asthma. PVT1 reduced
increased cellular proliferation and IL-6 release from ASMCs in severe
asthma.
[14]
BCYRN1 Upregulated – TRPC1 – BCYRN1 promoted proliferation and migration of rat airway smooth
muscle cells.
[21]
TUG1 Upregulated – miR-590-5p FGF1 TUG1 via sponging miR-590-5p/FGF1 promoted airway smooth muscle
cells proliferation and migration in asthma.
[20]
BCYRN1 Upregulated – miR-150 – autophagy activator schisandrin B by downregulating BCYRN1
expression inhibited proliferation and migration of rat ASMCs
[22]
TCF7 Upregulated asthmatic patients (n = 12) and healthy controls (n
= 12)
TIMMDC1 AKT TCF7 via targeting the TIMMDC1/Akt axis facilitated growth and
migration of ASMCs in asthma
[19]
LNC_000127 Upregulated patients at onset of Eos asthma (n = 12), at onset of
Neu asthma (n = 6), healthy controls (n = 12)
– – in Eos asthma, targeting LNC_000127 was effective in reducing Th2
inflammation in vitro
[15]
Malat1 Upregulated ASMCs isolated from 3 patients following lung
resection
miR-150 eIF4E/Akt Malat1 upregulated in ASMCs stimulated with platelet-derived growth
factor BB (PDGF-BB). Silencing of Malat1 using miR-150 and block of
eIF4E/Akt signaling inhibits PDGF-BB-induced ASMC proliferation and
migration.
[23]
ANRIL Upregulated plasma of 90 patients with asthma at remission (BA-
R) and 90 patients with asthma at exacerbation (BA-
E), and 90 healthy controls
miR-125a – expression of ANRIL/miR-125a used to investigate the disease





Upregulated 108 patients with asthma and 45 healthy controls – – specific lncRNAs aberrantly expressed in CD4+T cells useful as
biomarkers for diagnosis
[24]
MM9LINCRNAEXON12105+, AK089315 Upregulated – – – some of the altered lncRNAs involved in the alleviation of iPSC-MSC
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of up- and down- regulated miRNAs in asthma and their functions.
3. Atopic dermatitis (AD)
Wang et al. established an fluorescein isothiocyanate-induced an-
imal model of AD. Next, they assessed expression of ncRNAs and
mRNAs in this model using microarray technique. They showed dys-
regulation of 5766 lncRNAs, 4025 mRNAs, and 202 miRNAs after
provocation of the AD recurrence. Most notably, expression of 419
lncRNAs, 349 mRNAs and 23 miRNAs remained altered in the remission
stage [56]. In silico prediction steps led to identification of seven
lncRNAs that were subjected to expression assay in the ear tissue of
animals by qRT-PCR. They reported upregulation of lincRNA0016+,
uc008thl.1, uc029qxr.1, and AK077345, and down-regulation of
uc029ycn.1, ENSMUST00000164311, and ENSMUST00000149791.
Finally, they selected five lncRNAs (AK077345, uc008thl.1,
uc029ycn.1, ENSMUST00000164311, and ENSMUST00000149791)
with the highest expression change to identify their potential mRNA
targets [56]. These lncRNAs have been suggested as novel targets for
modulation of AD recurrence in mice [56].
Several studies assessed the role of miRNAs in the development of
AD. Expression profiling of miRNAs in AD facilitated identification of
pathogenetic pathways and helped in differentiation of this allergic
condition from other disorders like cutaneous T-cell lymphoma (CTCL)
or mycosis fungoides (MF). Ralfkiaer et al. showed differential ex-
pression of 38 miRNAs between early MF vs. AD. While miR-155, miR-
146a, 146b-5p, miR-342-3p and let-7i* were down-regulated in AD,
miR-203 and miR-205 had the opposite trend [57]. It is worth men-
tioning, that up-regulation of a certain miRNA in AD tissues does not
necessary imply the pathogenic role of this miRNA in the development
of this disorder. Rebane et al. described higher expression of miR-146a
in keratinocytes and chronic lesions of the skin in patients with AD.
However, the role of this miRNA was confirmed as suppression several
proinflammatory transcripts such as IFN-γ-inducible and AD-associated
chemokines CCL5, CCL8, and ubiquitin D (UBD) in vitro. Moreover, in
vivo experiments confirmed the presence of more robust inflammatory
responses in miR-146a-deficient mice. Functional studies revealed that
this miRNA inhibits the nuclear factor kappa-B signal transducers [58].
The function of up-regulated and down-regulated miRNAs in AD was
summarized in Table 3.
4. Allergic rhinitis (AR)
AR is characterized by induction of the inflammatory response in
the nasal mucosa after exposure to an allergen. The inflammatory re-
sponses comprise an immediate IgE-mediated mast cell degranulation
followed by recruitment of eosinophils, basophils, and T cells. Cells that
contribute in the late phase produce Th2 cytokines such as IL-4 and Il-5
which facilitate IgE synthesis and expansion of eosinophils [64]. Based
on the role of lncRNAs and miRNAs in the regulation of Th2 responses,
it is not surprising that altered expression of these transcript contributes
to the pathogenesis of AR. Ma et al. assessed lncRNA signature in nasal
mucosa of AR patients to predict possible function of these transcripts
in the pathogenesis of AR Their microarray investigation demonstrated
differential expression of a total of 2 259 lncRNAs (1,033 up-regulated
and 1,226 down-regulated) in the nasal mucosa of AR patients com-
pared with healthy controls. Analysis of lncRNA-mRNA co-expression
showed their enrichment in cellular signaling pathways associated with
AR development such as positive regulation of IL-13 production, Fc-
epsilon receptor-1 and NF-kappa B signaling pathways [65]. Another
microarray-based analysis reported differential expression several
lncRNAs including 110 upregulated and 48 downregulated lncRNAs in
Fig. 2. (A) miR-21 has been shown to be increased in allergic asthmatic mice, while IL-12 and STAT4 are decreased. These factors are involved in regulation of Th1/
Th2 balance. Dysregulated expression of these factors in asthma leads to Th2 dominance [29]. (B) IFN-γ is one of the Th1 cytokines which inhibits Th2 differ-
entiation. IL-4, -5 and -13 are Th2 cytokines which enhance production of eosinophils in the bone marrow and their transport to the lungs. While production of
eosinophils is increased by IL-5, IL-4 and -13 enhance expression of VCAM-1 on endothelial cells. Binding of VLA-4 molecules on eosinophils with VCAM-1 molecules
leads to extravasation of eosinophils. Then, IL-5 acts as an exotoxin to enhance transport of these cells to the lungs. Th2 cytokines increase survival of eosinophils as
well [54,55].
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Table 2
MiRNAs up- or down- regulated in asthma and summary of their function.





miR-1248 serum of asthmatics (n = 10) and non-asthmatic (n = 10) controls IL-5 – miR-1248 elevates Th2 cytokine levels. [27]
miR-371, miR-138, miR-544,
miR-145, miR-214
asthmatics (n = 30) and healthy
subjects (n = 25)
Runx3 – mirRNAs capable of combinatorial regulation of Runx3, modulates Th1/Th2 balance
in asthma.
[26]
miR-98 asthma patients(n = 20) and healthy subjects (n = 20) TSP1,
IL-13
miR-98 suppresses TSP1 expression in peripheral B cells of allergic asthmatics. [28]
miR-21 – IL-12, STAT4 – Axis of miR-22/IL-12/STAT4 participates in development of allergic asthma. [29]
miR-21 40 asthmatic children without inhaled corticosteroid, 40 steroid-sensitive
asthma children, 15 steroid-resistant asthma children, and 80 healthy
children
IL-12p35 – Circulating blood miRNA-21 predicts therapeutic response to ICS in asthma. [30]
miR-146a asthmatic children (n = 30) and healthy children (n = 30) EGFR – Upregulation of miR‑146a inhibits proliferation and promotes apoptosis of ASMCs in
asthma.
[31]
miR-19a airway epithelial cells isolated from mild asthmatic subjects (n = 9), and
severe asthmatic subjects (n = 6), and healthy controls (n = 9),





asthmatic children (n = 27) and non-asthmatic children (n = 21) – – miR-21 and miR-146a correlates with eosinophilic asthma, useful as biomarker. [33]
miR-146a – IL-5, IL-13 – miR-146a decreases influx of inflammatory cells into lung, suppresses OVA-specific





asthmatics treated with inhaled corticosteroids (n = 19) or without
inhaled corticosteroids (n = 16) and non-asthmatic controls (n = 12)
IL-13 – miRNAs increased in asthmatics compared to controls, expression in bronchial
epithelia of asthmatics positively correlated with IL-13
[35]
miR-155 – IL-33 – miR-155 required for allergen-induced ILC2 expansion and IL-33 production, asthma
mouse model
[36]
miR-21 – HDAC2 PI3K miR-21 induced in the lung by infection, during steroid-insensitive allergic airway
disease (SSIAAD) in BALB/c. miR-21. Amplifies PI3K–mediated suppression of
HDAC2 driving severe steroid-insensitive experimental asthma.
[37]
miR-21 – PTEN PI3K/Akt miR-21 through PTEN /PI3K/Akt signaling pathway modulates human ASMCs
proliferation and migration in asthma.
[38]
miR-21 – IL-12p35 IL-13Rα1,
STAT6
miR-21 through the IL-13Rα1-independent pathway overexpressed in mouse allergic
asthma
[39]
miR-155 7 asthmatics and 5 healthy subjects COX-2 PGE2 miR-155 assists overexpression of COX-2 in asthmatic ASMCs [40]
miR-221 4 asthmatics and 4 healthy subjects – – asthmatics and OVA-induced allergic mice have miR-221 upregulated, reduced
airway inflammation
[41]
miR-1165-3p 53 asthmatics and 22 healthy subjects – – circulating miR-1165-3p useful as a biomarker of asthma. [42]
miR-221 25 asthmatics and 22 healthy subjects SIRT1 – overexpression of miR-221 by targeting SIRT1 induces apoptosis and inhibits
proliferation in bronchial epithelial BEAS2B cells.
[43]
Down-regulated microRNA
miR-221-3p 77 asthmatics and 36 healthy subjects CXCL17 p38, MAPK miR-221-3p upregulates anti-inflammatory chemokine CXCL17, protective against
airway eosinophilic inflammation.
[44]
miR-192 7 mild asthmatics and 4 healthy subjects – – decreased miR-192 in blood of asthmatics [45]
miR-20b – – – intranasal administration of miR-20b increased the percentage of Gr1+CD11b +
myeloid-derived suppressor cells (MDSCs) and increased TGF-β in the lung of
asthmatic mice
[46]
miR-20b – – – miRNA-20b promotes accumulation of CD11b + Ly6G + Ly6Clow MDSCs in
asthmatic mice.
[47]
miR-485 – Smurf2 TGF-β/Smads miR-485 targeting Smurf2 through the TGF-β/Smads signaling pathway, suppresses
cell proliferation and promote cell apoptosis in mice with chronic asthma.
[48]
miR-142-3p mild (n = 5) and severe (n = 16) asthmatics – WNT miR-142-3p regulates the balance between proliferation and differentiation of
ASMCs
[49]
miR-26a, Let-7a, Let-7d, mir-
323, miR-21
serum of asthmatics (n = 10) and non-asthmatic (n = 10) controls – – miRNAs useful as a biomarkers for diagnosis of asthma. [27]
miR-17 asthmatics (n = 30) and healthy controls (n = 25) – – miR-17 useful as a biomarker for the diagnosis of asthma. [26]
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Table 2 (continued)





let-7a bronchial biopsies of 24 asthmatics and 10 controls – – let-7a useful as a biomarker to discriminate between asthma phenotypes. [50]
– IL-13 – exogenous let-7 mimic by targeting IL-13 alleviates asthmatic phenotype in OVA
allergic mice.
[51]




MiRNAs up-regulated in AD and summary of their function.
Up-regulated microRNA Numbers of clinical samples Targets/ Regulators Signaling Pathways Function Ref
miR-203, miR-205 atopic dermatitis (AD, n = 20), mycosis fungoides (MF, n = 13),
cutaneous T-cell lymphoma (CTCL, n = 42)
– – miRNA profiling in AD improves both diagnosis and risk prediction [57]
miR-155 serum of AD patients (n = 32) and
healthy
subjects (n = 31)
SOCS1 – miR-155 drives differentiation of Th17 cells, directly inhibits SOCS1 in
AD enhancing function of Th17 cells
[59]
skin biopsy from and patients with AD (n = 18) and healthy subjects
(n = 29)
CTLA-4 – miR-155suppresses CTLA-4 and by enhancing T-cell proliferation is
involved in the regulation of T-cell responses
[60]
miR-151a blood leukocytes
from AD patients (n = 117) and healthy subjects (n = 166)
IL12RB2 – miR-151a regulating IL12RB2 involved in the pathogenesis of AD [61]
miR-29b skin biopsy from AD patients (n = 21) and healthy control
subjects (n = 12)
BCL2L2 – miR-29b/Bcl2L2 axis is involved in the pathogenesis of AD [62]
miR‑146a serum of patients with AD (n = 25) and healthy controls
(n = 16)
SUMO1 – miR‑146a by targeting SUMO1 involved in the pathogenesis of AD [63]
miR-146a – CCL5 NF-kB in AD miR-146a controls NF-kB–dependent inflammatory response [58]




miR-155, miR-146a, miR-146b-5p, miR-
342-3p, Let-7i
atopic dermatitis (AD, n = 20), mycosis fungoides (MF, n = 13),
cutaneous T-cell lymphoma (CTCL, n = 42)
– – miRNA profiling in AD improves both diagnosis and risk prediction [57]
miR-677-3p, miR-770a-5p, miR-5119 atopic dermatitis (AD, n = 20), mycosis fungoides (MF, n = 13),
cutaneous T-cell lymphoma (CTCL, n = 42)
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the CD4 + T cells in an AR murine model. Differentially expressed
genes were enriched in some pathways such as regulation of calcium
ion transport, B cell activation and chemokine-signaling [66]. In a
human study, Qian et al. compared expression of ANRIL in nasal mu-
cosa samples between AR patients and non-atopic obstructive snoring
patients. Notably, up-regulation of ANRIL characterized AR patients.
Moreover, expression of this lncRNA positivly correlated with levels of
TNF-α, IL-4, IL-6, IL-13, and IL-17, whereas, it negatively correlated
with IL-10 and IFN-γ levels [67]. ANRIL expression also positively
correlated with: increased AR risk, severity and inflammation indices,
showing some diagnostic properties of this transcript in AR (Sensitivity
= 81.3 % and specificity = 56.3 %) [67]. Table 4 summarize the re-
sults of studies which reported up-regulation and down-regulation of
lncRNAs in AR.
Function of miRNAs was also investigated in the pathophysiology of
AR. Jia et al. assessed miRNA signature in nasal mucosa of AR patients
and non-atopic subjects using microarray technique and qRT-PCR. Up-
regulation of miR-126-5p, miR-19a-5p and miR-26a-5p was reported in
AR patients as compared to healthy subjects [69]. Hou et al. assessed
expression of miRNAs in AR mice before and after treatment with
ipratropium bromide (IB) effective in the control of AR symptoms.
Differential expression of 87 miRNAs in IB group was found by com-
parison with the placebo group. Notably, mmu‑miR‑124‑3p/5p,
‑133b‑5p, ‑133a‑3p/5p, ‑384‑3p, ‑181a‑5p, ‑378a‑5p and ‑3071‑5p
were among the most up-regulated miRNAs. Based on these observa-
tions, authors suggested that IB treatment regulated expression of im-
mune‑associated miRNAs in the nasal mucosa of allergic mice and
corresponded with amelioration of the nasal allergic symptoms [70].
Table 5 summarizes the results of studies which reported up-regulation
or down-regulation of miRNAs in AR.
One of the most practical aspects of miRNA profiling in human
disorders is application of differentially expressed molecules as pre-
dictive disease biomarkers. However, only a few studies assessed di-
agnostic performance of miRNA in diagnosis of AR. Table 6 summarizes
the results of these studies.
5. Urticaria
Urticaria is an acute or chronic dermal edema which is caused by
dilatation of vessels and leakage of fluid into the skin. Chronic spon-
taneous urticaria (CSU), also called chronic idiopathic urticaria (CIU),
is characterized by spontaneous development of wheals and/or an-
gioedema for more than 6 weeks without obvious triggering factors
[93]. Mast cells granules mediators have essential roles in the patho-
genesis of this disorder. CSU/CIU is an autoimmune disease [94]. A few
studies evaluated ncRNAs in the pathophysiology of this disorder. Lin
et al. reported on identification of miRNAs in CIU. By assessment of
miRNAs in plasma, profiles of these molecules were obtained in groups
comprising active hives or no hives and presence or absence of CIU.
Differentially expressed 16 miRNAs were found in patients with active
hives. MiR-2355-3p, miR-4264, miR-2355-5p, miR-29c-5p and miR-
361-3p were over-expressed in exacerbated CIU patients. Target pre-
diction of these miRNAs showed their enrichment in regulatory path-
ways such as TGF-β, glucocorticoid receptor, and p53 signaling. Some
other enriched terms were p21-activated kinase, phosphoinositide-3
kinase, protein kinase B and neuroactive ligand-receptor interaction
[95]. Zhang et al. explored the role of miRNAs in the CIU. Up-regula-
tion of miR-125a-5p and CCL17 was found in patients sera. Although
serum levels of miR-125a-5p were even higher in refractory CSU pa-
tients, its levels were down-regulated in patients who experienced re-
mission [96]. Table 7 summarizes the results of studies that reported
alterations of expression of miRNAs in urticaria.
6. Discussion
The current research on lncRNAs and miRNAs in allergic disorders is
summarized, however, no circRNA studies were conducted so far. These
data could be used for design of novel therapeutic strategies. Integrative
assessment of lncRNAs, miRNAs, circRNA with mRNA-encoded proteins
production is proposed as competing endogenous (ce) network. This
approach was successfully applied in AD [56]. A similar analysis in AR
identified mRNA-lncRNA network and suggested possible therapeutic
targets [65]. More recently, comprehensive assessment of lncRNA-
miRNA and mRNA-miRNA interaction data led to a construction of
lncRNA-miRNA-mRNA ceRNA network in asthma. These analyses
showed the importance of lncRNAs in the disease. Moreover, results
suggested tentative novel targets for treatment via drug repositioning
techniques [97]. Assessment of miRNAs/lncRNAs expression in paired
tissue and serum samples to compare patients vs. healthy subjects fa-
cilitates identification of disease biomarkers and explores the correla-
tion between their expressions in two tissues. The latter can elucidate
source of alterations in peripheral blood. Such comparative analyses
seems highly recommended in allergic diseases.
An imbalance between Th1 and Th2 responses is a common finding
in allergic conditions. Assessment of the specific roles of miRNAs and
lncRNAs in the regulation of these cells and identification of the ceRNA
network would facilitate recognition of biomarkers for these disorders.
This approach can be applied using the available expression profiles
from high-throughput studies. Moreover, variable expression of ncRNAs
in different stages of a disorder, e.g. remission or exacerbation, is ne-
cessary to fully address the function of these transcripts. Similarly, a
response of ncRNA levels to a treatment evaluated by appropriate
clinical scores would confirm importance of the observed alterations.
For example, alterations in the expressions of miRNAs were reported in
nasal mucosa after specific immunotherapy for AR in mice, thus in-
flicting miRNA in specific immunotherapy [98].
Table 4
LncRNAs up- or down- regulated in AR and summary of their function.
Upregulated lncRNA Numbers of clinical samples Function Ref
GABPA-9:1, NR_103763, CCL21, APOA2,
RAD9B-1:4
nasal mucosal from 19 patients with AR and
14 non-allergic patients
Expression of lncRNAs in AR patients provide insight into AR
pathogenesis.
[65]
FR022494, FR255904, FR169472 – Expression of lncRNAs in CD4 + T cells of AR murine model provide
insight into AR pathogenesis.
[66]
ANRIL nasal mucosal from 96 patients with AR and
96 controls
lncRNA ANRIL involved in the pathogenesis of AR [67]
Down-regulated lncRNA
GAS5 nasal epithelium from AR (n = 30) and
healthy subjects (n = 30)
GAS5 suppresses Th1 differentiation and promotes Th2 differentiation




nasal mucosa from 19 AR and 14 non-
allergic subjects





– Expression of lncRNAs in CD4 + T cells of an AR murine model provides
insight into AR pathogenesis.
[66]
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Table 5
MiRNAs up- or down-regulated in AR and summary of their function.
Up-regulated microRNA Numbers of clinical samples Targets/ Regulators Function Ref
miR-221,miR-142-3p nasal mucosa from 85 AR and 57 non-atopic subjects – miR-221 and miR-142-3p expressions novel and promising biomarker for risk of AR [71]
miR-30-5p, miR-199b-3p, miR-
203
extracellular vesicles from nasal mucus of 44 AR and 20 healthy controls – vesicle miRNA is regulator for the development of AR [72]
miR-375 – IL-4, IL-13, TSLP miR-375 is a regulator for the development of AR [73]
miR-135a – – miR‑135a corrects Th1/Th2 imbalance in AR mice [74]
miR-155 nasal mucosa from 28 AR and 26 non-atopic subjects IL-4, IL-5,
IL-9, IL-13





nasal mucosa from 48 AR and 50 control subjetcs – miR-126-5p, miR-19a-5p and miR-26a-5p novel biomarkers for AR risk [69]
miR-19a peripheral blood AR patients (n = 20) and healthy subjects (n = 20) IL-10 vitamin D3 represses mir-19a promoting specific immunotherapy (SIT) in AR [76]
miR-155, miR-205, miR-498 159 young adults stratified: AR + asthma (n = 36), nonallergic rhinitis (n = 39),
control (n = 34), AR (n = 50)
– miR-155, miR-205, and miR-498 importance in allergic inflammation of nasal mucosa [77]
Let-7a – OPN Let-7a regulates OPN expression promoting AR development in a mouse model [78]
miR-202-5p peripheral blood from 30 AR and 10 healthy subjects MATN2 miR‑202‑5p via targeting MATN2 participates in regulatory T‑cells differentiation and
function
[79]
miR-202-5p nasal mucosa from AR patients (n = 30) and healthy subjects (n = 10) MATN2 miR-202-5p by targeting MATN2 promotes M2 polarization in AR [80]
Down-regulated microRNA
miR-487b nasal mucosa from 20 patients with AR and 20 control patients IL-33,
ST2
miR-487b through inhibition of the IL-33/ST2 signaling pathway mitigates allergic
rhinitis
[81]
miR-133b – Nlrp3 overexpression of miR-133b via targeting Nlrp3 inhibits OVA-specific IgE and allergic




extracellular vesicles from nasal mucus from 44 AR patients and 20 healthy
controls
– vesicle miRNA regulates development of AR [72]
miR-146a nasal mucosa from 24 AR children




miR-146a considered as a biomarker for management of AR patients. [83]
miR-21 20 cord blood samples with and without elevated cord blood IgE (CBIgE)




lower expression of miR-21 and higher expression of TGFBR2 in.CB associated with
antenatal IgE production and development of AR.
[84]
miR-let-7e nasal mucosa from 23 patients with AR and 18 control patients SOCS4, JAK1/STAT3 miR‑let‑7e through the SOCS4/JAK1/STAT3 signaling pathway regulates progression
and development of AR.
[85]
miR-21 – PTEN traditional chinese medicine yupingfeng upregulates PTEN-induced miRNA-21 while
improving imbalance in theTh1/Th2 ratio in allergic rhinitis
[86]
miR-155, miR-181a 25 AR children and 20 healthy children IL-10 decreased regulatory cells (Tregs)-derived miR-155 and miR-181a correlated with
reduced number and function of Tregs in AR children.
[87]
let-7e 159 young adult subjects subdivided into control (n = 34), AR (n = 50), AR +
asthma (n = 36), and non-allergic rhinitis (NAR, n = 39)
– let-7e importance in allergic inflammation of nasal mucosa. [77]
miR-106b – Egr-2 miR-106b by targeting Egr-2 regulates pro-allergic properties of dendritic cells and Th2
polarization in vitro
[88]
miR-143 nasal mucosal from AR (n = 23) and non-AR sibjects (n = 18). IL13Ra1 miR-143 by targeting IL13Ra1 inhibits IL-13-induced inflammatory cytokine and mucus
production in nasal epithelial cells of AR patients
[89]
miR30a-5p 20 AR and 20 control subjects SOCS3 miR30a-5p/SOCS3 involved in the pathogenesis of AR [90]
miR‐181a, miR‐155 20 AR and 20 healthy subjects SOCS1, SIRT1,
IL‐10, TGF‐β, PI3K/
Akt
miR‐155 and miR‐181a closely correlated with the proliferation and function of Tregs in
AR
[91]
miR‑15a‑5p nasal mucosa of 20 patients with long-term AR and 20 non-AR subjects ADRB2 in AR stimulated by IL-13, ADRB2 inhibits inflammatory response of NECs, miR-15a-5p
has a negative regulatory effect on ADRB2
[92]
miR-375 – JAK2, STAT3 miR-375 via inhibiting JAK2/STAT3 pathway ameliorates AR and prevents nasal
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Table 6
Diagnostic power of miRNAs in AR.
Samples number Area under curve Sensitivity Specificity Univariate cox regression Multivariate cox regression Ref
nasal mucosa from 85 patients with AR and
57 non-atopic patients
0.622 for miR-221 and 0.762 for
miR-142-3p
35.3 % for miR-221 and 78.8 %
for miR-142-3p
86.0 % for miR-221 and 64.9 %
for miR-142-3p
– [71]
nasal mucosa from 48 AR patients and 50
controls
0.685 for miR-126-5p, 0.742 for
miR-19a-5p, 0.719 for miR-26a-5p
89.6 % for all 70% for all expression positively correlated
with the risk of AR.
expression independently associated with
increased risk of AR.
[69]
Table 7
Summary of urticaria studies that reported alterations in expression of miRNAs.





Upregulated 12 patients stratified to: normal chronic urticaria index and no active hives; positive disease
index no active hives; active hives with a negative disease index; active hives and positive disease
index
– modulation of inflammation-related
pathways
[95]
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The presented data appeals for the role of both lncRNAs and
miRNAs, and possibly circRNAs in the pathogenesis of asthma, AR, AD
and urticaria. Identified miRNAs/lncRNAs alterations awaits replica-
tion studies.
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